Kevin D. Freeman
CIK: 0001522478
Kevin D. Freeman's purchase track record
How the stock did after each of Kevin D. Freeman's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 6 since April 22, 2024
Stock higher 6 months later
33%
3 months: 50%
Median 6-month return
-15.7%
3 months: -0.8%
Beat the S&P 500
17%
median -26.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/23/2025 | GALT | $20K | -29.1% | -21.8% | +6.6% |
| 7/17/2025 | GALT | $14K | +74.7% | +9.0% | +10.3% |
| 12/24/2024 | GALT | $8K | +110.7% | +188.1% | +0.9% |
| 10/16/2024 | GALT | $30K | -51.3% | -47.9% | -9.7% |
| 6/20/2024 | GALT | $6K | +17.4% | -17.4% | +7.2% |
| 4/22/2024 | GALT | $7K | -18.9% | -14.1% | +16.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GALT | ▲ Buy | Open Market | 5,500 | $20K | 12/23/2025 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $14K | 7/17/2025 | View on chart |
| GALT | ▲ Buy | Open Market | 10,000 | $8K | 12/24/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 1,300 | $3K | 10/17/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $14K | 10/16/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $14K | 10/16/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 2,500 | $6K | 6/20/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 2,500 | $7K | 4/22/2024 | View on chart |
| GALT | ▼ Sell | Other | 2,063 | $0 | 4/9/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 10,000 | $14K | 10/28/2022 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $7K | 5/19/2022 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $9K | 4/18/2022 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $10K | 1/19/2022 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $11K | 12/6/2021 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $12K | 12/6/2021 | View on chart |
| GALT | ▲ Buy | Open Market | 2,000 | $6K | 10/29/2021 | View on chart |
| GALT | ▲ Buy | Open Market | 2,000 | $6K | 10/21/2021 | View on chart |
| GALT | ▲ Buy | Open Market | 3,000 | $10K | 10/19/2021 | View on chart |
| GALT | ▲ Buy | Open Market | 3,000 | $12K | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.